The Swedish Medical Products Agency approves extension of Diamyd® trial
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that DIAGNODE-1, an open clinical pilot trial where the diabetes vaccine Diamyd® is tested by given directly into the lymph node, has been approved by the Swedish Medical Products Agency and the Ethics Committee to be expanded from nine to fifteen patients.The pilot trial DIAGNODE-1 is the first trial of its kind, where a low dose of Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The concept, for which Diamyd Medical has submitted a patent application, can be compared to